Published in J Neurooncol on April 17, 2014
Polymeric drug delivery for the treatment of glioblastoma. Neuro Oncol (2015) 0.90
Bionanotechnology and the future of glioma. Surg Neurol Int (2015) 0.78
Design, synthesis, and evaluation of cisplatin-containing EGFR targeting bioconjugates as potential therapeutic agents for brain tumors. Onco Targets Ther (2016) 0.77
Current status and perspectives of interventional clinical trials for glioblastoma - analysis of ClinicalTrials.gov. Radiat Oncol (2017) 0.75
Insights into molecular therapy of glioma: current challenges and next generation blueprint. Acta Pharmacol Sin (2017) 0.75
The Long and Winding Road: From the High-Affinity Choline Uptake Site to Clinical Trials for Malignant Brain Tumors. Adv Pharmacol (2016) 0.75
Setting the stage: local delivery of cytoreductive agents for the treatment of glioblastoma. Neuro Oncol (2015) 0.75
mir-218-2 promotes glioblastomas growth, invasion and drug resistance by targeting CDC27. Oncotarget (2016) 0.75
Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review. World J Surg Oncol (2016) 0.75
Solasonine inhibits glioma growth through anti-inflammatory pathways. Am J Transl Res (2017) 0.75
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 14.15
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 12.52
Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin (2010) 5.53
Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res (2006) 4.80
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol (2008) 4.39
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol (2010) 3.43
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res (2009) 3.00
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol (2006) 2.82
Response criteria for glioma. Nat Clin Pract Oncol (2008) 2.69
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov (2012) 2.61
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol (2006) 2.49
Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res (2011) 2.40
Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. J Clin Oncol (2012) 2.39
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol (2009) 2.32
The role of imaging in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. J Neurooncol (2014) 2.32
Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol (2009) 2.29
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal (2009) 2.23
Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery (2012) 2.19
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A (2013) 2.14
The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 2.13
End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol (2009) 2.13
Epidemiology of brain metastases. Curr Oncol Rep (2012) 2.09
Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol (2012) 2.08
The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells. Int J Cancer (2009) 1.98
The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 1.96
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol (2011) 1.95
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol (2009) 1.92
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol (2011) 1.92
Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther (2008) 1.84
Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist (2006) 1.83
Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol (2009) 1.83
Central nervous system cancers. J Natl Compr Canc Netw (2013) 1.82
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov (2011) 1.77
Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro Oncol (2006) 1.76
Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res (2011) 1.69
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol (2009) 1.66
Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol (2008) 1.64
Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol (2010) 1.63
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol (2011) 1.53
Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res (2009) 1.52
Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol (2011) 1.50
Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: clinical article. J Neurosurg (2013) 1.46
Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat Med (2013) 1.46
Central nervous system complications of cancer therapy. J Support Oncol (2012) 1.43
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol (2012) 1.42
Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol (2011) 1.42
An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol (2008) 1.39
Glioblastoma in the elderly: the Memorial Sloan-Kettering Cancer Center Experience (1997-2007). Cancer (2009) 1.35
Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol (2009) 1.35
Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness. Cancer Sci (2007) 1.35
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol (2007) 1.34
Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol (2004) 1.33
Advances in meningioma therapy. Curr Neurol Neurosci Rep (2009) 1.30
Brain metastases. Curr Opin Neurol (2005) 1.29
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro Oncol (2012) 1.27
Glioma therapy in adults. Neurologist (2006) 1.26
Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol (2011) 1.26
Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol (2003) 1.26
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol (2006) 1.25
Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A (2011) 1.24
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol (2009) 1.21
Response assessment in neuro-oncology. Curr Oncol Rep (2011) 1.19
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol (2008) 1.18
Methodology used to develop the AANS/CNS management of brain metastases evidence-based clinical practice parameter guidelines. J Neurooncol (2009) 1.17
Prognostic factors in adult brainstem gliomas: a multicenter, retrospective analysis of 101 cases. J Neurooncol (2008) 1.17
Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev Anticancer Ther (2007) 1.14
Central nervous system cancers. J Natl Compr Canc Netw (2011) 1.13
The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 1.13
Therapeutic strategies for inhibiting invasion in glioblastoma. Expert Rev Neurother (2009) 1.13
Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res (2007) 1.13
Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin Cancer Res (2009) 1.11
Multimodal actions of neural stem cells in a mouse model of ALS: a meta-analysis. Sci Transl Med (2012) 1.10
SDF-1 and CXCR4 are up-regulated by VEGF and contribute to glioma cell invasion. Cancer Lett (2005) 1.10
Medical management of brain tumor patients. Neurol Clin (2007) 1.09
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol (2010) 1.08
An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines (2013) 1.08
Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older. Cancer (2012) 1.08
The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 1.07
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist (2010) 1.05
The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 1.04
Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Cancer Chemother Pharmacol (2007) 1.04
Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro Oncol (2010) 1.04
Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol (2013) 1.03
Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol (2013) 1.03
Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys (2010) 1.03
The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. J Natl Cancer Inst (2007) 1.03
DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. PLoS One (2012) 1.02
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol (2006) 1.02
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J Neurooncol (2010) 1.02
Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol (2012) 1.02
Evidence-based guidelines for the management of brain metastases. Neurosurg Clin N Am (2011) 1.02
Morphological characteristics of brain tumors causing seizures. Arch Neurol (2010) 1.01
Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncol (2012) 1.01
Longitudinal MRI evidence for decreased survival among periventricular glioblastoma. J Neurooncol (2010) 1.01
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clin Cancer Res (2013) 1.00
Emerging antiangiogenic treatments for gliomas - efficacy and safety issues. Curr Opin Neurol (2008) 0.99